Calidi Biotherapeutics, Inc. (CLDI): Entry into a Material Definitive Agreement
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering SAN DIEGO, September 17, 2026 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines,
How this was made
The 30-second read
Why it matters
The $1.2 M capital raise adds working‑capital but dilutes existing shareholders; short‑term price movement expected to be muted.
Market read
Primary disclosure of a small capital raise; limited trading relevance for most investors.
What to watch
Potential pipeline milestones could make the modest cash more valuable than its size suggests.
Background
Calidi Biotherapeutics (NYSE American: CLDI) is a biotech developing targeted genetic medicines via its RedTail platform.
Ticker impact
Calidi Biotherapeutics filed an 8‑K announcing a $1.2 million registered direct offering of 1,025,640 shares at $1.17 each.
Potential slight upside if market views cash as runway, but dilution may cap gains.
The raise is small relative to market cap and likely already priced in; traders may watch for short‑term volatility.
Market effects
Provides modest funding for biotech R&D; unlikely to shift sector sentiment.
Limited to US small‑cap biotech market.
Minimal global impact.
Counterpoint
The offering could be a sign of cash constraints, suggesting downside risk.
Key entities
- companyCalidi Biotherapeutics, Inc.
Issuer of the registered direct offering.
